Veracyte, Inc. (NASDAQ:VCYT) Receives $55.88 Average Price Target from Brokerages

Posted by Geri Gentry on Aug 2nd, 2026

Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $57.3750.

VCYT has been the subject of several research reports. Jefferies Financial Group initiated coverage on Veracyte in a research note on Monday, April 13th. They issued a “buy” rating and a $45.00 target price for the company. Guggenheim lifted their price target on shares of Veracyte from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Wolfe Research initiated coverage on shares of Veracyte in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $55.00 price objective for the company. Zacks Research cut shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Canaccord Genuity Group increased their target price on shares of Veracyte from $42.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, July 14th.

Check Out Our Latest Analysis on Veracyte

Veracyte Trading Down 22.5%

VCYT opened at $46.32 on Tuesday. The stock has a 50-day moving average price of $53.72 and a 200-day moving average price of $42.32. Veracyte has a 12-month low of $22.92 and a 12-month high of $60.91. The stock has a market capitalization of $3.70 billion, a P/E ratio of 32.85 and a beta of 1.93.

Veracyte (NASDAQ:VCYT – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The firm had revenue of $150.32 million for the quarter, compared to analyst estimates of $144.59 million. Veracyte had a return on equity of 9.41% and a net margin of 20.37%.The company’s revenue was up 15.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.44 EPS. On average, equities research analysts predict that Veracyte will post 1.25 EPS for the current year.

Insiders Place Their Bets

In other Veracyte news, CFO Rebecca Chambers sold 3,561 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $49.73, for a total transaction of $177,088.53. Following the completion of the sale, the chief financial officer directly owned 173,280 shares in the company, valued at $8,617,214.40. This represents a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Annie Mcguire sold 3,176 shares of Veracyte stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $49.76, for a total value of $158,037.76. Following the completion of the transaction, the executive vice president owned 137,240 shares in the company, valued at approximately $6,829,062.40. This represents a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 206,696 shares of company stock valued at $10,079,058 over the last three months. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Veracyte

Large investors have recently bought and sold shares of the stock. Osaic Holdings Inc. grew its stake in shares of Veracyte by 289.9% in the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 893 shares during the last quarter. Torren Management LLC purchased a new stake in Veracyte in the 4th quarter worth approximately $37,000. Empowered Funds LLC bought a new stake in shares of Veracyte in the 4th quarter worth approximately $42,000. Smartleaf Asset Management LLC increased its stake in shares of Veracyte by 159.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 679 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Veracyte by 146.4% during the fourth quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 864 shares during the period.

Key Veracyte News

Here are the key news stories impacting Veracyte this week:

Positive Sentiment: Second-quarter adjusted earnings were $0.54 per share, above the $0.43 analyst consensus and up from $0.44 a year earlier. Revenue of $150.3 million also exceeded estimates of approximately $144.6 million. Veracyte Q2 Earnings and Revenues Surpass Estimates
Positive Sentiment: Total revenue increased 15% year over year, while testing revenue rose 19% to $145.7 million, indicating continued demand for Veracyte’s diagnostic testing business. Veracyte Announces Second Quarter 2026 Financial Results
Positive Sentiment: Management raised its full-year 2026 revenue guidance to $590 million-$596 million, above the prior outlook implied by the approximately $585 million analyst consensus. Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised
Neutral Sentiment: The earnings call and presentation provided additional detail on quarterly performance and the raised 2026 outlook, but investors may be looking for further evidence that growth can accelerate beyond the current guidance range. Veracyte Q2 2026 Earnings Call Transcript
Negative Sentiment: Despite beating quarterly estimates and raising revenue guidance, commentary questioning whether Veracyte is now fully valued suggests the results may not have exceeded the high expectations embedded in the stock. With shares trading at a relatively demanding earnings multiple, investors appear to be taking profits on the news. Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.